Αρχική World News 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung Cancer,...

2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung Cancer, Breast Cancer, and Sarcoma

In the annual Research Round Up series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field presented at the 2021 ASCO Annual Meeting?” In this episode, 3 experts discuss new research from the meeting in lung cancer, breast cancer, and sarcoma.

Listen below, and subscribe to Cancer.Net Podcasts wherever you listen to podcasts for new episodes in this series throughout the summer.

Research on new treatments for non-small cell lung cancer

Dr. Charu AggarwalDr. Charu Aggarwal, the 2021 Cancer.Net Associate Editor for Lung Cancer, discusses results from 3 studies evaluating new treatments for non-small cell lung cancer (NSCLC). First, she discusses the phase 2 CodeBreaK 100 clinical trial, which evaluated whether using the targeted therapy sotorasib (Lumakras) to treat people with metastatic non-small cell lung cancer with a KRAS G12C mutation shrank the tumors. [2:35] Next, she discusses a 5-year update from the phase 3 PACIFIC clinical trial on whether treating people with stage III (3) non-small cell lung cancer using the immunotherapy durvalumab (Imfinzi) following chemotherapy with radiation therapy helped them live longer. [4:46] Finally, she discusses the phase 3 Impower010 clinical trial, which tested whether treating people with early-stage non-small cell lung cancer with the immunotherapy atezolizumab (Tecentriq) following surgery and chemotherapy reduced their risk of recurrence, or the cancer coming back. [6:46]

Advances in treating early-stage breast cancer

Dr. Lynn HenryDr. Lynn Henry, the 2021 Cancer.Net Associate Editor for Breast Cancer, discusses results from 2 studies in breast cancer, the first of which was the phase 3 OlympiA clinical trial. In this study, researchers were evaluating whether treating people with a BRCA mutation and early-stage, HER2-negative breast cancer using olaparib (Lynparza), a type of targeted therapy called a PARP inhibitor, decreased the likelihood of the cancer returning. [10:40] Dr. Henry also discusses the final results from the phase 3 PROMISE-GIM6 clinical trial. Sometimes, ovarian suppression is given to preserve a patient’s ability to have children, or fertility, after treatment with chemotherapy ends. This trial was observing whether ovarian suppression combined with chemotherapy impacted a patient’s risk of recurrence. [12:47]

Research highlights for the treatment of sarcoma

Dr. Vicki KeedyDr. Vicki Keedy, the 2021 Cancer.Net Associate Editor for Sarcoma, discusses results from 2 studies testing new treatments for sarcoma. The first study, the phase 2 SPEARHEAD-1 clinical trial, looked at whether treating people with metastatic synovial sarcoma or myxoid/round cell liposarcoma using afami-cel, a type of immunotherapy called T-cell receptor therapy, shrank the tumors. [15:38] The second study evaluated whether treating people with metastatic synovial sarcoma using catequentinib, a type of targeted therapy called a tyrosine kinase inhibitor, slowed down their tumor growth compared to treatment with the chemotherapy dacarbazine (DTIC). [18:42]

Disclosure information for this podcast’s speakers can be found in their individual biographies, which are linked to in the paragraphs above.

Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.

Cancer.Net podcasts are edited for length and content.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...